Vivo Opportunity Fund Holdings, L.P. 13D and 13G filings for SAB Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-03 4:30 pm Purchase | 2025-09-29 | 13G | SAB Biotherapeutics, Inc. SABS | Vivo Opportunity Fund Holdings, L.P. | 25,931,000 9.990% | 25,931,000 (New Position) | Filing |